Betamethasone Dipropionate Emollient Spray vs Halobetasol Propionate Foam

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: Glucocorticoid receptor · full Psoriasis pipeline

Betamethasone Dipropionate Emollient Spray · Sernivo

Marketed by Primus Pharmaceuticals and partners

Approved in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Halobetasol Propionate Foam · Lexette

Rights held by Mayne Pharma; US product discontinued

Approved in Psoriasissmall molecule
Reliable signal

NCT02742441 · Phase 3 · completed

The trial randomized 409 participants to active foam or vehicle foam and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was met, with treatment success in 30.7% versus 7.4% of participants at Day 15 (p<0.001).

Reported efficacy

Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4% (met)

Result source: NCT02742441

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBetamethasone Dipropionate Emollient SprayHalobetasol Propionate Foam
PASI 75—Not reported—Not posted · NCT02367911
PASI 90—Not reported—Not posted · NCT02367911
PASI 100—Not reported—Not posted · NCT02367911
sPGA 0/1—Not reported—Not posted · NCT02367911
DLQI, change—Not reported—Not posted · NCT02367911

PASI 75

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Foam
—Not posted · NCT02367911

PASI 90

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Foam
—Not posted · NCT02367911

PASI 100

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Foam
—Not posted · NCT02367911

sPGA 0/1

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Foam
—Not posted · NCT02367911

DLQI, change

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Foam
—Not posted · NCT02367911
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Betamethasone Dipropionate Emollient Spray: registry results are on file for Psoriasis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Betamethasone Dipropionate Emollient Spray: 0 of 4 rows · Halobetasol Propionate Foam: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricHalobetasol Propionate Foam
Dropout rate
2.9%a
NCT02742441 · Phase 3
show 4 more results
1.3%
NCT02368210 · Phase 3
7%
NCT02367911 · Phase 3
0%
NCT01698333 · Phase 2 · registry result, not featured evidence
0%
NCT01700985 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%a
NCT02742441 · Phase 3
show 4 more results
0%
NCT02368210 · Phase 3
—
NCT02367911 · Phase 3
—
NCT01698333 · Phase 2 · registry result, not featured evidence
—
NCT01700985 · Phase 2 · registry result, not featured evidence
Serious AEs
0%a
NCT02742441 · Phase 3
show 4 more results
0%
NCT02368210 · Phase 3
0%
NCT02367911 · Phase 3
0%
NCT01698333 · Phase 2 · registry result, not featured evidence
0%
NCT01700985 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
headache 1.5% (placebo 1.5%)
application site pain 1% (placebo 0.5%)
back pain 0.5% (placebo 0%)
NCT02742441 · Phase 3
show 4 more results
abdominal pain 1.3% (placebo 0%)
application site pain 1.3% (placebo 0%)
hordeolum 1.3% (placebo 0%)
NCT02368210 · Phase 3
sinusitis 1.4% (placebo 0%)
trichorrhexis 1.4% (placebo 0%)
application site dryness 0% (placebo 1.4%)
NCT02367911 · Phase 3
acth stimulation test abnormal 24%
nasal congestion 4%
pharyngitis 4%
NCT01698333 · Phase 2 · registry result, not featured evidence
influenza like illness 4.3% (placebo 0%)
pharyngitis 0% (placebo 4.8%)
upper respiratory tract infection 0% (placebo 9.5%)
NCT01700985 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Halobetasol Propionate Foam

IGA "Treatment Success 30.7% (n=205) vs 7.4% (n=204) placebo @ 2.14wk
responder rate · % of participants
NCT02742441 · Phase 3
show 2 more results
9.5% (n=199) vs 3.6% (n=196) placebo @ 1.14wk
NCT02742441 · Phase 3
18.3% (n=71) vs 9.6% (n=73) placebo @ 2.14wk
NCT02367911 · Phase 3
Scaling 33.7% (n=205) vs 9.8% (n=204) placebo @ 2.14wk
responder rate · % of participants
Scaling
NCT02742441 · Phase 3
show 4 more results
14.2% (n=205) vs 3.6% (n=204) placebo @ 1.14wk
Scaling
NCT02742441 · Phase 3
28% (n=75) vs 5.3% (n=76) placebo @ 2.14wk
Scaling
NCT02368210 · Phase 3
12.2% (n=75) vs 3.9% (n=76) placebo @ 1.14wk
Scaling
NCT02368210 · Phase 3
32.4% (n=71) vs 13.7% (n=73) placebo @ 2.14wk
Scaling
NCT02367911 · Phase 3
Pruritus -4.3 vs -2.5 placebo score @ 2.14wk
absolute change · score
NCT02742441 · Phase 3
show 1 more result
-4.4 vs -2 placebo score @ 2.14wk
NCT02368210 · Phase 3
BSA -1.5% (n=199) vs -0.2% (n=196) placebo @ 2.14wk
absolute change · percentage points
NCT02742441 · Phase 3
show 2 more results
-0.3% (n=23) vs 0% (n=20) placebo @ 1.14wk
NCT01700985 · Phase 2 · registry result, not featured evidence
-1.3% (n=23) vs 0% (n=20) placebo @ 2.14wk
NCT01700985 · Phase 2 · registry result, not featured evidence
IGA 25.3% (n=75) vs 3.9% (n=76) placebo @ 2.14wk
responder rate · % of participants
NCT02368210 · Phase 3
show 1 more result
8.1% (n=75) vs 2.6% (n=76) placebo @ 1.14wk
NCT02368210 · Phase 3
BSA -0.9% (n=75) vs -0.2% (n=76) placebo @ 2.14wk
absolute change · percentage points
Change in % BSA at Day 15
NCT02368210 · Phase 3
PGA 52.2% (n=23) vs 0% (n=20) placebo @ 2.14wk
absolute change · percentage points
NCT01700985 · Phase 2 · registry result, not featured evidence
PGA 0% (n=23) vs 0% (n=20) placebo @ 1.14wk
responder rate · % of participants
NCT01700985 · Phase 2 · registry result, not featured evidence
show 1 more result
52.2% (n=23) vs 0% (n=20) placebo @ 2.14wk
NCT01700985 · Phase 2 · registry result, not featured evidence
PGA 2-point Improvement 0% (n=23) vs 0% (n=20) placebo @ 1.14wk
responder rate · % of participants
NCT01700985 · Phase 2 · registry result, not featured evidence
show 1 more result
52.2% (n=23) vs 0% (n=20) placebo @ 2.14wk
NCT01700985 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Betamethasone Dipropionate Emollient Spray's landscape · Halobetasol Propionate Foam's landscape